- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
X4 Pharmaceuticals Inc (XFOR)
"X4 Pharmaceuticals Inc stock price live, this page displays NASDAQ XFOR stock exchange data. View the XFOR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the X4 Pharmaceuticals Inc real time stock price chart below.
What Is the X4 Pharmaceuticals Inc Stock Price Today?
The X4 Pharmaceuticals Inc stock price today is 2.920.
What Is the Stock Symbol for X4 Pharmaceuticals Inc?
The stock symbol for X4 Pharmaceuticals Inc is ""XFOR.""
What Stock Exchange Does X4 Pharmaceuticals Inc Trade On?
X4 Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is X4 Pharmaceuticals Inc a Good Stock to Buy?
Determining whether X4 Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XFOR quote. (ISIN: US98420X2027)"
What Is the X4 Pharmaceuticals Inc Stock Price Today?
The X4 Pharmaceuticals Inc stock price today is 2.920.
What Is the Stock Symbol for X4 Pharmaceuticals Inc?
The stock symbol for X4 Pharmaceuticals Inc is ""XFOR.""
What Stock Exchange Does X4 Pharmaceuticals Inc Trade On?
X4 Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is X4 Pharmaceuticals Inc a Good Stock to Buy?
Determining whether X4 Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XFOR quote. (ISIN: US98420X2027)"
NASDAQ
Currency in USD
2.920
0.000(0.00%)
Closed·
After Hours
3.000+0.100(+3.448%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.840
2.998
52 wk Range
2.840
33.900
XFOR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
More Info
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8402.998
52 wk Range
2.84033.900
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XFOR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
42.667
Upside
+1,361.19%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
X4 Pharmaceuticals Inc Company Profile
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.
X4 Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- X4 Pharmaceuticals reports Q1 2025 EPS of $0.04, beating -$0.12 forecast; revenue reaches $28.81M vs $12.03M expected
- Strategic restructuring aims to reduce annual spending by $30-35M; company maintains $90M cash, sufficient until H1 2026
- FORWARD trial enrollment to complete by Q3/Q4 2025; top-line data expected H2 2026; EMA approval for WHIM indication targeted Q1 2026
- Stock declines 1.42% in premarket despite earnings beat; company faces high R&D/SG&A expenses and clinical trial enrollment challenges
- CEO expresses confidence in meeting milestones; CCO highlights high compliance rates for daily oral medication in chronic neutropenia market
Last Updated: 2025/05/01, 15:26
Read Full TranscriptCompare XFOR to Peers and Sector
Metrics to compare | XFOR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXFORPeersSector | |
|---|---|---|---|---|
P/E Ratio | 1.2x | −0.6x | −0.5x | |
PEG Ratio | 0.01 | −0.01 | 0.00 | |
Price/Book | 0.7x | 1.3x | 2.6x | |
Price / LTM Sales | 0.5x | 18.1x | 3.0x | |
Upside (Analyst Target) | - | 311.0% | 54.7% | |
Fair Value Upside | Unlock | 4.5% | 8.4% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 42.667
(+1,361.19% Upside)
Earnings
Latest Release
May 01, 2025
EPS / Forecast
0.04 / -0.12
Revenue / Forecast
28.81M / 12.03M
FAQ
What Is the X4 Pharmaceuticals (XFOR) Stock Price Today?
The X4 Pharmaceuticals stock price today is 2.92
What Stock Exchange Does X4 Pharmaceuticals Trade On?
X4 Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for X4 Pharmaceuticals?
The stock symbol for X4 Pharmaceuticals is "XFOR."
What Is the X4 Pharmaceuticals Market Cap?
As of today, X4 Pharmaceuticals market cap is 16.85M.
What Is X4 Pharmaceuticals's Earnings Per Share (TTM)?
The X4 Pharmaceuticals EPS (TTM) is 2.16.
When Is the Next X4 Pharmaceuticals Earnings Date?
X4 Pharmaceuticals will release its next earnings report on 30 Jul 2025.
From a Technical Analysis Perspective, Is XFOR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.